Chemistry and Pharmacology of Drugs of Abuse Annual Symposium

其他项目信息--项目摘要/摘要 这项提议是对为期两天的“化学和化学”研讨会的更新。 《滥用药物的药理学》(CPDA)专题讨论会，于2016年首次由 马萨诸塞州波士顿东北大学药物发现中心(CDD)。该计划的主要目标是 研讨会是对最新的、重要的、与研究相关的进展的跨学科展示 正在进行与物质使用障碍(SUD)相关的(前期)临床研究。物质使用障碍(SODS)和 成瘾是对全球公共卫生的普遍威胁，这种威胁的性质正在不断演变和 正在改变。我们的目标是解决目前关于SUD疾病机制和知识的空白 治疗是我们在解决这些医学挑战方面的局限性的根源。 一个主要的主题是药物化学，结构生物学，药理学，行为学 药理学和临床实践，为新药物的设计、合成、优化和(临床前)分析提供信息 用于治疗潜力的药物。SUD的生物学和病因学很复杂。行为、环境和 (EPI)遗传因素共同调节神经元回路，影响脆弱性、认知、社会行为和 情绪状态有助于建立一种sud表型。这些神经生物学过程的细节 都没有被很好地理解。此外，寻找和吸毒的更好的标准化动物范例是 需要更好地模拟临床SUD病理，并可用于准确评估新的潜力 苏打类药物。尽管取得了重大进展，但安全和有效的药物数量有限，令人沮丧 可用于实现持久戒毒的药物疗法。我们的持续目标是将会议的重点完全集中在 物质使用障碍和聚集了来自这些领域的领先的从业者。此外，还有 对高危SUD人群的紧急威胁，如缺乏情感药物治疗和 需要持续的警觉和努力来抗击。我们的目标是在每个主题中包含解决紧急问题的主题 由NIDA社区领袖和领先研究确定的年度计划。这样的聚会提供了一个丰富的 让年轻科学家接触这一领域的机会。我们的目标是激励和鼓励下一代 研究人员致力于这一努力。我们已经做出了相当大的努力来欢迎科学家 我们的目标是扩大这些努力。 一次关于应对紧急威胁的重点会议具有很高的价值，并取得了许多成果。 得到从基础研究人员到医疗保健的SUD研究社区和不同支持者的支持 医疗服务提供者和公共卫生官员。这包括来自生物技术(例如Astraea Treeutics)的科学家， 领先的生物医学研究中心(例如斯克里普斯研究所)、研究密集型临床中心(例如， 麦克莱恩医院/哈佛医学院、西奈山伊坎医学院)和来自 波士顿市长办公室。我们的目标是进一步提高我们研讨会的公众形象。

OTHER PROJECT INFORMATION – PROJECT SUMMARY/ABSTRACT This proposal is a renewal for the tremendously successful two-day symposium “Chemistry and Pharmacology of Drugs of Abuse” (CPDA) symposium that first took place in 2016 under the auspices of the Center for Drug Discovery (CDD), Northeastern University, Boston, Massachusetts. The primary aim of the symposium is to serve as an interdisciplinary exposition of the most recent, important, research-related advances in (pre)clinical research related to Substance Use Disorder (SUD). Substance Use Disorders (SUDs) and addiction are pervasive threats to global public health and the nature of the threat is ever evolving and changing. Our goal is to address gaps in current knowledge concerning SUD disease mechanisms and treatments that are at the root of our limitations in solving these medical challenges. A major theme is the integration of medicinal chemistry, structural biology, pharmacology, behavioral pharmacology and clinical practice to inform the design, synthesis, optimization, and (pre)clinical profiling of new agents for their therapeutic potential. SUD biology and etiology are complex. Behavioral, environmental, and (epi)genetic factors conspire to modulate neuronal circuits to affect vulnerability, cognition, social behavior, and emotional state in ways that help establish a SUD phenotype. The details of these neurobiological processes are not well understood. In addition, better standardized animal paradigms of drug-seeking and -taking are required that better model clinical SUD pathology and can be used to accurately assess the potential of novel SUD drugs. Despite significant advances, there is a frustratingly limited number of safe and affective pharmacotherapies available to attain durable abstinence. Our continuing aim is to focus the meeting entirely on Substance Use Disorder and bring together leading practitioners from each of these fields. Moreover, there are emergent threats to at-risk SUD populations such as “designer drugs” that lack affective pharmacotherapy and require ongoing vigilance and effort to combat. We aim to include topics that address emergent issues in each year’s program as identified by NIDA community leaders and leading research. Such a gathering offers a rich opportunity to expose young scientists to the field. We aim to inspire and encourage the next generation of researchers to devote themselves to this endeavor. We have made considerable efforts to welcome scientists from underserved and underrepresented populations and we aim to expand these efforts. A focused meeting on SUD responsive to emergent threats is of high value and has garnered much support by the SUD research community and diverse constituencies, from basic researchers to healthcare providers and public-health officials. This included scientists from biotechnology (e.g. Astraea Therapeutics), leading biomedical research centers (e.g. Scripps Research Institute), research-intensive clinical centers (e.g., McLean Hospital/Harvard Medical School, Icahn School of Medicine at Mount Sinai) and representatives from the City of Boston Mayor’s office. Our goal is to further raise the public profile of our symposium.